NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Nuvalent Inc (NUVL) Stock Analysis

Nuvalent Inc (NUVL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NUVL

$123.96

$0.00 (0.00%)

Last trade July 21, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NUVL with… →

NUVL Key Statistics

As of Jul 21, 2026
Trading
Open
$123.96
Previous Close
$123.96
52-Week Range
71.13–123.99
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.14
Valuation
Market Cap
$9.81B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−6.06
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$425.38M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+50.33%
Dividend and dates
Avg Volume
2.33M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NUVL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+23.23%
2025+28.50%
2024 (partial year)−7.51%

As of July 21, 2026.

NUVL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$425.38M—
2024$0.00−$260.76M—
2023$0.00−$126.22M—
2022$0.00−$81.85M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$414.31M−$425.38M—
2024$0.00—−$280.37M−$260.76M—
2023$0.00—−$149.49M−$126.22M—
2022$0.00—−$86.11M−$81.85M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NUVL Valuation vs Biotechnology Median

Median of 656 stocks
MetricNUVLBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Nuvalent Inc (NUVL) is capitalised at $9.81B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 234 employees.

The most recent close on file for NUVL is $123.96, dated July 21, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $71.13 to $123.99. The latest close sits 74.27% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $425.38M. The reported profit margin is 0%. Trailing earnings per share are −6.06.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 1.14. Annualized volatility over the trailing 1 year is 57.58%. The trailing one-year price return is +50.33%. The stored price history starts on December 19, 2024, and the total return since then is +46.46%.

Growth & Income

The record shows no dividend for NUVL.

2026 is still running; the price is +23.23% year to date. The record holds one complete calendar year, 2025, which returned +28.50%.

Peer Comparison

Nuvalent Inc (NUVL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nuvalent Inc NUVL $9.81B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Nuvalent Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of July 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Nuvalent Inc

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Visit website →